Literature DB >> 16575495

Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease.

Vicente Giner Galvañ1, María Rosa Oltra, Diego Rueda, María José Esteban, Josep Redón.   

Abstract

Antimalarial drugs are used for the control of mild manifestations of autoimmune diseases due to their low toxicity. Hydroxychloroquine (HCQ), a alpha-hydroxylated derivative of chloroquine, is usually preferred because of its higher tolerability. Mild and unspecific gastrointestinal symptoms are the main secondary effects related to HCQ use. Less than 1% of subjects show liver enzyme increase, although the percentage can be as high as 50% in subjects with chronic liver disease. A woman with mixed connective tissue disease who developed a reversible acute hepatitis shortly after the initiation of low-dose HCQ is presented. Two previous cases of patients with acute liver failure have previously been published. All three cases have been reported in the absence of previous liver disease. It seems to be a dose-dependent, idiosyncratic, and molecule-specific toxic effect and must be considered, taking into account the potential bad prognosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16575495     DOI: 10.1007/s10067-006-0218-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  10 in total

Review 1.  Antimalarials.

Authors:  M J Van Beek; W W Piette
Journal:  Dermatol Clin       Date:  2001-01       Impact factor: 3.478

Review 2.  Questions answered and a $1 million question raised concerning lupus erythematosus tumidus: is routine laboratory surveillance testing during treatment with hydroxychloroquine for skin disease really necessary.

Authors:  R D Sontheimer
Journal:  Arch Dermatol       Date:  2000-08

3.  Guidelines for the management of rheumatoid arthritis: 2002 Update.

Authors: 
Journal:  Arthritis Rheum       Date:  2002-02

4.  Long-term effectiveness of antimalarial drugs in rheumatic diseases.

Authors:  J A Aviña-Zubieta; G Galindo-Rodriguez; S Newman; M E Suarez-Almazor; A S Russell
Journal:  Ann Rheum Dis       Date:  1998-10       Impact factor: 19.103

5.  Bullous rash and brown urine in a systemic lupus erythematosus patient treated with hydroxychloroquine.

Authors:  D C Kutz; A J Bridges
Journal:  Arthritis Rheum       Date:  1995-03

6.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

7.  Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis.

Authors:  C H van Jaarsveld; Z N Jahangier; J W Jacobs; A A Blaauw; G A van Albada-Kuipers; E J ter Borg; H L Brus; Y Schenk; M J van Der Veen; J W Bijlsma
Journal:  Rheumatology (Oxford)       Date:  2000-12       Impact factor: 7.580

8.  Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis.

Authors:  M Y Mok; W L Ng; M F Yuen; R W Wong; C S Lau
Journal:  Clin Exp Rheumatol       Date:  2000 May-Jun       Impact factor: 4.473

9.  Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.

Authors:  Janet E Pope; Paul Hong; Barry E Koehler
Journal:  J Rheumatol       Date:  2002-02       Impact factor: 4.666

10.  Fulminant hepatic failure secondary to hydroxychloroquine.

Authors:  A J Makin; J Wendon; S Fitt; B C Portmann; R Williams
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

  10 in total
  16 in total

1.  Still disease and the liver-an underappreciated association.

Authors:  Kieron B L Lim; Thomas D Schiano
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-12

2.  Clinical significance of chronic hepatitis B virus infection in patients with primary Sjögren's syndrome.

Authors:  Ming-Han Chen; Liang-Tsai Hsiao; Ming-Huang Chen; Chang-Youh Tsai; Yi-Hsiang Huang; Chung-Tei Chou
Journal:  Clin Rheumatol       Date:  2011-08-02       Impact factor: 2.980

3.  Troxis necrosis, a novel mechanism for drug-induced hepatitis secondary to immunomodulatory therapy.

Authors:  Christina H Wei; Andrew Penunuri; George Karpouzas; Wayne Fleishman; Anuj Datta; Samuel W French
Journal:  Exp Mol Pathol       Date:  2015-08-20       Impact factor: 3.362

4.  Treatment of rheumatoid arthritis in patients with concomitant chronic hepatitis C infection.

Authors:  Amy M Joseph
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-02       Impact factor: 5.346

5.  Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with COVID-19.

Authors:  Melissa Barreto Falcão; Luciano Pamplona de Góes Cavalcanti; Nivaldo Menezes Filgueiras Filho; Carlos Alexandre Antunes de Brito
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

6.  Acute hepatitis B or exacerbation of chronic hepatitis B-that is the question.

Authors:  Efrat Orenbuch-Harroch; Liran Levy; Eldad Ben-Chetrit
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

Review 7.  Hydroxychloroquine retinopathy.

Authors:  I H Yusuf; S Sharma; R Luqmani; S M Downes
Journal:  Eye (Lond)       Date:  2017-03-10       Impact factor: 3.775

8.  A novel role for α-tocopherol transfer protein (α-TTP) in protecting against chloroquine toxicity.

Authors:  Mototada Shichiri; Nozomu Kono; Yuta Shimanaka; Masaki Tanito; Daisy E Rotzoll; Yasukazu Yoshida; Yoshihisa Hagihara; Hiroshi Tamai; Hiroyuki Arai
Journal:  J Biol Chem       Date:  2011-12-06       Impact factor: 5.157

Review 9.  Current and New Drugs for COVID-19 Treatment and Its Effects on the Liver.

Authors:  Sandeep Satsangi; Nitin Gupta; Parul Kodan
Journal:  J Clin Transl Hepatol       Date:  2021-04-19

Review 10.  SARS-CoV2 and immunosuppression: A double-edged sword.

Authors:  Quirino Lai; Gabriele Spoletini; Giuseppe Bianco; Dario Graceffa; Salvatore Agnes; Massimo Rossi; Jan Lerut
Journal:  Transpl Infect Dis       Date:  2020-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.